Atlas Trials

A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy

Clinical trial NCT07235202 · RECRUITING

Trial details

NCT number
NCT07235202
Sponsor
Shenzhen Majory Biotechnology Co., Ltd.
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Pancreatic Ductal Adenocarcinoma (PDAC)
Start date
2025-12-24
Primary completion
2028-06-22
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.